Novartis Vaccines
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Novartis Vaccines sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).
Novartis Vaccines: 32 sponsored US clinical trials, none currently recruiting.
Novartis Vaccines sponsors 32 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 15 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Meningococcal Disease, with 2 trials.
Top-decile sponsor footprint
Novartis Vaccines ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
32 total, page 1 of 1
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
NCT02256488
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
NCT02140762
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
NCT01992536
Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
NCT01992094
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
NCT01992107
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
NCT01928472
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
NCT01823536
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
NCT01855945
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
NCT01857206
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
NCT01776554
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
NCT01776541
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921
Safety Surveillance of MenACWY-CRM Vaccine in Children
NCT01452438
Safety of MenACWY-CRM Vaccination in Adolescents
NCT01452464
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
NCT01272180
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects
NCT01162122
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
NCT01148017
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
NCT01018732
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
NCT01000311
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
NCT00996307
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
NCT00972816
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
NCT00856297
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
NCT00616421
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
NCT00626327
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
NCT00630331
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
NCT00474526
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
NCT00450437
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
NCT00297817
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
NCT00264576
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children
NCT00262028
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
NCT00262041
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 13 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
How the Novartis Vaccines archive is shaped
32 indexed studies, none listed as recruiting (0% open); 32 completed (100%).
Phase mix: 15 late (III/IV) vs 15 early (I/II) (balanced across stages).
Top condition: Meningococcal Disease (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Novartis Vaccines: archived-pipeline peers nationwide
Peers matched on 32 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Novartis Vaccines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 32 archived trials
- Aerie Pharmaceuticals · 32 trials · 0% recruiting
- Allina Health System · 32 trials · 3% recruiting
- Ardea Biosciences · 32 trials · 0% recruiting
- Hebrew SeniorLife · 32 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Novartis Vaccines page
32 registered trials is a research-attention snapshot, not an endorsement of Novartis Vaccines or any single study.
- None of Novartis Vaccines's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Meningococcal Disease is the condition Novartis Vaccines studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Meningococcal Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis Vaccines pipeline card: 32 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.